CD52 Double Nickase Plasmid (h): sc-403151-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD52 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD52 Double Nickase Plasmid (h) and CD52 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD52. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD52 Antibody (HI186): sc-51560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD52 Double Nickase Plasmid (h) | sc-403151-NIC | 20 µg | $410.00 | |||
CD52 Double Nickase Plasmid (h2) | sc-403151-NIC-2 | 20 µg | $410.00 |
CD52 encodes a small glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein broadly expressed on lymphocytes and other leukocyte subsets. It contributes to immune cell biology by influencing membrane organization and signaling microdomains, with downstream effects on activation state, adhesion, and immune homeostasis. CD52 expression is widely used as a marker for immunophenotyping and for dissecting lineage composition and functional states across hematopoietic compartments. Dysregulated CD52-positive cell populations are frequently studied in the context of immune-mediated inflammation and hematologic malignancy research, where altered immune cell abundance and signaling dynamics are central features.
CD52 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD52 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD52. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD52 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD52-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.